<DOC>
	<DOCNO>NCT02715908</DOCNO>
	<brief_summary>To evaluate long-term safety include immunogenicity efficacy LBEC0101 50 mg subcutaneous weekly injection co-administered MTX</brief_summary>
	<brief_title>A Study Evaluate Long-term Safety Efficacy LBEC0101 Subjects With Active Rheumatoid Arthritis Despite Methotrexate ( MTX )</brief_title>
	<detailed_description>study evaluate long-term safety include immunogenicity efficacy LBEC0101 50 mg subcutaneous weekly injection co-administered MTX additional 48 week ( total 100 week include 52 week treatment period Study LG-ECCL002 ) subject complete treatment period phase III clinical study LBEC0101 ( Study No . LG-ECCL002 ) .</detailed_description>
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<criteria>Patients complete treatment period Study LGECCL002 Patients require continuous treatment rheumatoid arthritis upon investigator 's discretion For childbearing female patient surgically nonsterile male patient , agree avoid pregnancy use proper contraceptive method study . Patients make voluntary decision participate clinical study give voluntary write consent comply instruction full understanding inform study Patients deem difficult participate extension study due adverse event occur Study LGECCL002 , upon investigator 's discretion screening Patients least 10 swollen joint ( total 66 assess joint ) least 12 tender joint ( total 68 assess joint ) screen Women pregnancy lactation , patient plan pregnant study period Patients ineligible clinical study upon investigator 's discretion</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>April 2016</verification_date>
</DOC>